bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

• Market Cap: $7.08M
• Dividend Yield: N/A
• Average Volume (3M): 3.66M
• Price to Earnings (P/E): ―
• Beta (1Y): -2.69
• Revenue Growth: 4.99%
• EPS Growth: 22.58%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -5.10
• Shares Outstanding: 1,338,029
• 10 Day Avg. Volume: 10,856,612
• 30 Day Avg. Volume: 3,656,468
• PEG Ratio: 0.07
• Price to Book (P/B): 4.24
• Price to Sales (P/S): 1.18
• P/FCF Ratio: -1.50
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: 2.95
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $0.50
• Price Target Upside: -90.55% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2

• Rating: 38 Underperform
• Price Target: $0.00 ▼(-100.00% Downside)

The overall stock score is primarily driven by the company's weak financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Product Innovation

The introduction of new case studies for CyPath® Lung highlights ongoing innovation, potentially enhancing the company's competitive edge in early cancer detection.

Revenue Streams

Diverse revenue streams from product sales and potential licensing agreements provide a stable foundation for future growth and resilience against market fluctuations.

Free Cash Flow Improvement

Improvement in free cash flow indicates better cash management, which can support ongoing R&D and operational activities, enhancing long-term sustainability.

Negative Factors

Negative Profitability

Persistent negative profitability and margins suggest ongoing operational challenges, which could hinder investment in growth and innovation.

Rising Leverage

Increasing leverage may strain financial flexibility, limiting the company's ability to invest in strategic initiatives and manage economic downturns.

Declining Revenue

A decline in revenue suggests potential market share loss or reduced demand, which could impact long-term growth prospects and competitive positioning.

bioAffinity Technologies, Inc. Business Overview & Revenue Model

Company Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

How the Company Makes Money

bioAffinity Technologies, Inc. generates revenue primarily through the commercialization of its diagnostic and therapeutic products. The company sells its products to healthcare providers, laboratories, and research institutions. Additionally, bioAffinity may enter into licensing agreements and partnerships with other biotechnology and pharmaceutical companies to co-develop or distribute its products, providing additional revenue streams. Research grants and funding from governmental and non-governmental organizations might also contribute to the company's earnings by supporting its research and development activities.

bioAffinity Technologies, Inc. Financial Statement Overview

Summary

The company is facing significant financial challenges with declining revenues, negative profitability, and increasing leverage. Despite a slight improvement in free cash flow, the overall financial health remains weak, with negative equity and persistent losses.

Income Statement

The income statement shows a challenging financial position with negative margins across the board. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 34.41%, but a significant net loss with a net profit margin of -110.53%. Revenue has decreased by 12.81% in the TTM period, indicating a decline in sales. The company has consistently reported negative EBIT and EBITDA margins, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity in the TTM period, leading to a negative equity ratio. The debt-to-equity ratio has increased to 0.92, indicating rising leverage. Return on equity is significantly negative, reflecting the company's inability to generate profits from its equity base.

Cash Flow

Cash flow analysis shows a slight improvement in free cash flow growth at 16.54% in the TTM period, but operating cash flow remains negative. The operating cash flow to net income ratio is -1.92, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.68M	9.36M	2.53M	4.80K	0.00	0.00
Gross Profit	2.29M	3.38M	791.62K	4.34K	-4.82K	-22.24K
EBITDA	-11.00M	-8.33M	-7.63M	-5.61M	-2.20M	-6.86M
Net Income	-11.69M	-9.04M	-7.94M	-8.15M	-6.33M	-7.27M
Balance Sheet
Total Assets	4.75M	6.51M	8.22M	12.18M	1.45M	145.60K
Cash, Cash Equivalents and Short-Term Investments	802.84K	1.11M	2.82M	11.41M	1.36M	83.11K
Total Debt	670.00K	1.50M	1.58M	251.75K	11.36M	10.01M
Total Liabilities	6.89M	3.91M	3.37M	1.14M	17.24M	15.22M
Stockholders Equity	-2.14M	2.60M	4.86M	11.04M	-15.79M	-15.07M
Cash Flow
Free Cash Flow	-7.75M	-7.34M	-6.06M	-4.29M	-2.05M	-2.21M
Operating Cash Flow	-7.68M	-7.26M	-6.04M	-4.07M	-2.05M	-2.21M
Investing Cash Flow	-73.62K	-79.08K	-2.21M	-219.99K	0.00	-2.89K
Financing Cash Flow	7.75M	5.63M	-344.98K	14.34M	3.33M	1.72M

bioAffinity Technologies, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 5.29 is below the 20-day moving average (MA) of 6.56, below the 50-day MA of 7.86, and below the 200-day MA of 13.90, indicating a bearish trend. The MACD of -0.93 indicates Positive momentum. The RSI at 42.95 is Neutral, neither overbought nor oversold. The STOCH value of 11.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.

bioAffinity Technologies, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	62 Neutral	$28.21M	-14.40	-35.47%	―	27.05%	55.03%
TRIB	48 Neutral	$19.32M	-0.37	90.36%	―	-4.02%	-6.31%
MYNZ	44 Neutral	$7.10M	―	-358.07%	―	―	―
BNGO	41 Neutral	$16.19M	-0.04	-163.82%	―	-25.02%	85.08%
BIAF	38 Underperform	$7.08M	―	-1802.45%	―	4.99%	22.58%
INBS	38 Underperform	$10.17M	-0.54	-352.75%	―	-1.90%	87.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

bioAffinity Technologies, Inc. Corporate Events

bioAffinity Technologies Unveils New CyPath® Lung Case Study

On September 9, 2025, bioAffinity Technologies announced a new case study demonstrating the effectiveness of its CyPath® Lung test in identifying lung cancer in a patient with ground-glass nodules. The test shifted the patient’s care from a prolonged period of watchful waiting to immediate treatment, highlighting its potential to improve patient outcomes by providing timely, actionable information. This advancement underscores the product’s capability to reduce uncertainty in diagnosing difficult-to-assess lung nodules, positioning bioAffinity Technologies as a key player in enhancing lung cancer diagnostics.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Prepares for H.C. Wainwright Conference

bioAffinity Technologies, Inc., a Delaware corporation, has prepared presentation materials for use in various presentations about the company’s operations and performance. These materials are intended for events such as the H.C. Wainwright 27th Annual Global Investment Conference scheduled from September 8, 2025, to September 10, 2025. The presentation materials, furnished as Exhibit 99.1, are part of a Current Report on Form 8-K and are not considered filed under the Securities Exchange Act of 1934. This announcement highlights the company’s efforts to engage with investors and stakeholders through strategic presentations, potentially impacting its market visibility and investor relations.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies’ CyPath® Lung Test Featured in U.S. Medicine

On September 3, 2025, bioAffinity Technologies announced that U.S. Medicine Magazine featured their CyPath® Lung test in its pulmonary issue, recognizing its potential to enhance lung cancer detection and reduce costs for the Department of Veterans Affairs. The test has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, with significant potential savings for healthcare systems by reducing unnecessary follow-up procedures. This recognition underscores the test’s value in improving patient outcomes and its economic benefits, particularly for veterans at higher risk of developing lung cancer.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Amends Warrant Floor Price in Recent Agreement

On September 2, 2025, bioAffinity Technologies, Inc. announced an agreement with warrant holders to amend the Floor Price of its May and August 2025 Warrants, increasing it from $0.10 to $0.15. This amendment, effective as of August 12, 2025, resulted in a reduction of shares issuable upon exercise of the May 2025 Warrants from 53,377,497 to 35,584,997, while the August 2025 Warrants remain subject to shareholder approval.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Appoints New Board Members

On August 12, 2025, bioAffinity Technologies appointed Roberto Rios and John J. Oppenheimer to its Board of Directors, enhancing the company’s financial and clinical expertise. The appointments are part of a strategic move to bolster the company’s growth and development in diagnostics for lung diseases, following Gary Rubin’s resignation from the board.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Secures $1.2M Through Private Placement

On August 13, 2025, bioAffinity Technologies, Inc. entered into a securities purchase agreement with institutional and accredited investors to issue and sell Series B Convertible Preferred Stock and warrants in a private placement, raising approximately $1.2 million in gross proceeds. The company also executed a warrant inducement transaction with an existing investor, which involved exercising existing warrants at a reduced price and issuing new warrants, resulting in additional proceeds of $253,000. The proceeds from these transactions are intended for working capital and general corporate purposes, potentially strengthening the company’s financial position and supporting its operational goals.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Sees Surge in CyPath® Lung Test Sales

On August 13, 2025, bioAffinity Technologies announced a significant increase in sales of its CyPath® Lung test, with July’s test volume surging 72% over the prior monthly average. Despite this growth, the company faces potential delisting from the Nasdaq Capital Market due to non-compliance with listing requirements, but plans to appeal the decision to stay its securities’ suspension.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.